Gilead Sciences (GILD) 'Crushed' the Quarter, Piper Jaffray Says; Remains Top Large-Cap Biotech Pick

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. NKE
9. MU
10. AWK

Go back to Gilead Sciences (GILD) 'Crushed' the Quarter, Piper Jaffray Says; Remains Top Large-Cap Biotech Pick

Gilead Sciences (GILD) Bullish Stance Reiterated at BMO Capital Amid 'Strong' Q1

May 1, 2015 7:00 AM EDT

BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $159 price target on Gilead Sciences (NASDAQ: GILD) following "strong" Q1 results after the close with room to expand in HCV.

Birchenough commented, "We are maintaining our Outperform rating on the shares of GILD... More

Gilead Sciences (GILD) Bullish Stance Reiterated at Baird on 'Beat and Raise' Q1

May 1, 2015 6:42 AM EDT

Baird analyst Brian Skorney reiterated an Outperform rating and $126 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q1.

Skorney commented, "A sizeable beat should be enough to support the stock and perhaps stop the sector slide. We expect... More

Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue Guidance

April 30, 2015 4:02 PM EDT

Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.76, $0.48 better than the analyst estimate of $2.28. Revenue for the quarter came in at $7.59 billion versus the consensus estimate of $6.81 billion.

Gilead Sciences sees FY2015 revenue of $28-29 million, versus the consensus of $28.50... More